China's TOT Biopharm starts stage II construction for commercial production of MAb drugs

17 October 2016

Chinese bio-pharmaceutical developer, manufacturer and marketer of anti-cancer drugs TOT Biopharm has formally broke ground on its stage II construction of the second phase monoclonal antibody (MAb) drug production facility at Suzhou Industrial Park.

The company develops new drugs with high technical barriers and economic value as well as anti-cancer products specifically designed for the healthcare environment in China, offering patients the most suitable and affordable product portfolio for the benefit of the greater good.

TOT Biopharm completed the $100 million construction of its stage I plant cancer drugs plant and put it into operation in 2012. The company continued to increase investment, resulting in the establishment of a new monoclonal antibody drug factory in 2016, a facility that will focus on manufacturing monoclonal antibody drugs and antibody-drug conjugates (ADCs).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK